Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Nilotinib 150mg oral capsule [Tasigna]
DRUG
2 trials
Sponsors
Georgetown University
, Hamad Medical Corporation
Conditions
Chronic Myeloid Leukemia - Chronic Phase
Parkinson Disease
Parkinsons Disease With Dementia
Phase 2
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease
Completed
NCT02954978
Georgetown University
Parkinson Disease, Parkinsons Disease With Dementia
Start: 2017-01-01
End: 2020-07-01
Updated: 2026-06-12
Phase 3
Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia
Terminated
NCT03079505
Hamad Medical Corporation
Chronic Myeloid Leukemia - Chronic Phase
Start: 2017-08-03
End: 2018-09-23
Updated: 2019-01-23
Related Papers
Targeting protein kinases in Parkinson's disease: the emerging role of phytoconstituents.
2025-07-18
CSF MicroRNAs Reveal Impairment of Angiogenesis and Autophagy in Parkinson Disease
Neurology Genetics
2021-11-12
27 citations
Dasatinib versus nilotinib as upfront therapy for treatment naïve chronic myeloid leukemia chronic phase
Medicine Case Reports and Study Protocols
2021-02-01
3 citations
4564 Nilotinib alters microRNAs that regulate specific autophagy and ubiquitination genes in the cerebrospinal fluid of Parkinson’s patients
Journal of Clinical and Translational Science
2020-06-01
2 citations
Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease
JAMA Neurology
2019-12-16
164 citations